{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:34:46Z","timestamp":1794044086126,"version":"4.8.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03599-z","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:10:36Z","timestamp":1776355836000},"page":"2820-2835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis"],"prefix":"10.1007","volume":"43","author":[{"given":"Theodoros","family":"Panou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"10290","key":"3599_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195\u2013211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3.","journal-title":"Lancet"},{"issue":"1","key":"3599_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"MA Mall","year":"2024","unstructured":"Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. Nat Rev Dis Primers. 2024;10(1):53. https:\/\/doi.org\/10.1038\/s41572-024-00538-6.","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"3599_CR3","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann H, Ratjen F. Cystic fibrosis. N Engl J Med. 2023;389(18):1693\u2013707. https:\/\/doi.org\/10.1056\/NEJMra2216474.","journal-title":"N Engl J Med"},{"issue":"2","key":"3599_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2021.23280","volume":"327","author":"TM Endres","year":"2022","unstructured":"Endres TM, Konstan MW. What is cystic fibrosis? JAMA. 2022;327(2):191. https:\/\/doi.org\/10.1001\/jama.2021.23280.","journal-title":"JAMA"},{"issue":"6","key":"3599_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2337\/dc23-0380","volume":"46","author":"MS Putman","year":"2023","unstructured":"Putman MS, Norris AW, Hull RL, et al. Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes. Diabetes Care. 2023;46(6):1112\u201323. https:\/\/doi.org\/10.2337\/dc23-0380.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"3599_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","volume":"18","author":"A Granados","year":"2019","unstructured":"Granados A, Chan CL, Ode KL, et al. Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis. J Cyst Fibros. 2019;18(Suppl 2):S3\u20139. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.016.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"3599_CR7","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","volume":"18","author":"KL Ode","year":"2019","unstructured":"Ode KL, Chan CL, Granados A, Moheet A, Moran A, Brennan AL. Cystic fibrosis related diabetes: medical management. J Cyst Fibros. 2019;18(Suppl 2):S10\u20138. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.003.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"3599_CR8","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jcf.2019.08.011","volume":"18","author":"BA Kaminski","year":"2019","unstructured":"Kaminski BA, Goldsweig BK, Sidhaye A, et al. Cystic fibrosis related diabetes: nutrition and growth considerations. J Cyst Fibros. 2019;18(Suppl 2):S32\u20137. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.011.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"3599_CR9","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697\u2013708. https:\/\/doi.org\/10.2337\/dc10-1768.","journal-title":"Diabetes Care"},{"issue":"5","key":"3599_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jcf.2024.06.007","volume":"23","author":"A Santhakumar","year":"2024","unstructured":"Santhakumar A, Lewis F, Pickles J, et al. Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: a single centre experience. J Cyst Fibros. 2024;23(5):853\u20136. https:\/\/doi.org\/10.1016\/j.jcf.2024.06.007.","journal-title":"J Cyst Fibros"},{"issue":"9","key":"3599_CR11","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","volume":"106","author":"A Kelly","year":"2021","unstructured":"Kelly A, Sheikh S, Stefanovski D, et al. Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance. J Clin Endocrinol Metab. 2021;106(9):2617\u201334. https:\/\/doi.org\/10.1210\/clinem\/dgab365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3599_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","volume":"4","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type\u00a02 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525\u201336. https:\/\/doi.org\/10.1016\/S2213-8587(15)00482-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Supplement_1","key":"3599_CR13","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S183\u2013215. https:\/\/doi.org\/10.2337\/dc26-S009.","journal-title":"Diabetes Care"},{"issue":"8","key":"3599_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24(8):631\u201350. https:\/\/doi.org\/10.1038\/s41573-025-01183-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3599_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","volume":"49","author":"A Coriati","year":"2025","unstructured":"Coriati A, Potter KJ, Gilmour J, et al. Cystic fibrosis-related diabetes: a first Canadian clinical practice guideline. Can J Diabetes. 2025;49(1):19-28.e16. https:\/\/doi.org\/10.1016\/j.jcjd.2024.09.001.","journal-title":"Can J Diabetes"},{"issue":"5","key":"3599_CR16","doi-asserted-by":"publisher","first-page":"E851","DOI":"10.1210\/jc.2010-2460","volume":"96","author":"P Kuo","year":"2011","unstructured":"Kuo P, Stevens JE, Russo A, et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis\u2014effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab. 2011;96(5):E851\u20135. https:\/\/doi.org\/10.1210\/jc.2010-2460.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3599_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jcf.2011.11.001","volume":"11","author":"M Hillman","year":"2012","unstructured":"Hillman M, Eriksson L, Mared L, et al. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros. 2012;11(2):144\u20139. https:\/\/doi.org\/10.1016\/j.jcf.2011.11.001.","journal-title":"J Cyst Fibros"},{"issue":"10","key":"3599_CR18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.2337\/db22-0399","volume":"71","author":"SC Nyirjesy","year":"2022","unstructured":"Nyirjesy SC, Peleckis AJ, Eiel JN, et al. Effects of GLP-1 and GIP on islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis. Diabetes. 2022;71(10):2153\u201365. https:\/\/doi.org\/10.2337\/db22-0399.","journal-title":"Diabetes"},{"issue":"7","key":"3599_CR19","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1210\/jc.2013-4417","volume":"99","author":"SJ Perano","year":"2014","unstructured":"Perano SJ, Couper JJ, Horowitz M, et al. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial. J Clin Endocrinol Metab. 2014;99(7):2486\u201393. https:\/\/doi.org\/10.1210\/jc.2013-4417.","journal-title":"J Clin Endocrinol Metab"},{"key":"3599_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2025.100392","volume":"40","author":"WS Lei","year":"2025","unstructured":"Lei WS, Chen X, Zhao L, et al. Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis. J Clin Transl Endocrinol. 2025;40:100392. https:\/\/doi.org\/10.1016\/j.jcte.2025.100392.","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"3599_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76722-1","volume":"14","author":"SA Gharib","year":"2024","unstructured":"Gharib SA, Vemireddy R, Castillo JJ, et al. Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs. Sci Rep. 2024;14(1):25689. https:\/\/doi.org\/10.1038\/s41598-024-76722-1.","journal-title":"Sci Rep"},{"key":"3599_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47745-w","volume":"9","author":"D Khan","year":"2019","unstructured":"Khan D, Kelsey R, Maheshwari RR, et al. Short-term CFTR inhibition reduces islet area in C57BL\/6 mice. Sci Rep. 2019;9:11244. https:\/\/doi.org\/10.1038\/s41598-019-47745-w.","journal-title":"Sci Rep"},{"issue":"11","key":"3599_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70510","volume":"15","author":"LM Voetmann","year":"2025","unstructured":"Voetmann LM, Rolin B, Kirk RK, et al. Liraglutide upregulates the Cftr gene and regulates the mucus transcriptome profile in Brunner\u2019s glands in mice. Clin Transl Med. 2025;15(11):e70510. https:\/\/doi.org\/10.1002\/ctm2.70510.","journal-title":"Clin Transl Med"},{"issue":"3","key":"3599_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/dom.13544","volume":"21","author":"MC Geyer","year":"2019","unstructured":"Geyer MC, Sullivan T, Tai A, et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes Obes Metab. 2019;21(3):700\u20134. https:\/\/doi.org\/10.1111\/dom.13544.","journal-title":"Diabetes Obes Metab"},{"key":"3599_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2024.100375","volume":"38","author":"A Ahmed","year":"2024","unstructured":"Ahmed A, Ankireddypalli A, Harindhanavudhi T, et al. Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review. J Clin Transl Endocrinol. 2024;38:100375. https:\/\/doi.org\/10.1016\/j.jcte.2024.100375.","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"3599_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","volume":"24","author":"S Park","year":"2025","unstructured":"Park S, Jain R, Mirfakhraee S. Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis. J Cyst Fibros. 2025;24(1):40\u20136. https:\/\/doi.org\/10.1016\/j.jcf.2024.08.005.","journal-title":"J Cyst Fibros"},{"key":"3599_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2025.10.006","author":"A Horvit","year":"2026","unstructured":"Horvit A, Kaput K, Neece A, et al. Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index. J Cyst Fibros. 2026. https:\/\/doi.org\/10.1016\/j.jcf.2025.10.006.","journal-title":"J Cyst Fibros"},{"issue":"7","key":"3599_CR28","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf104","volume":"3","author":"GI Sydney","year":"2025","unstructured":"Sydney GI, Do T, West WA, et al. Cystic fibrosis and hemochromatosis carriers may be prone to glucagon-like peptide-1 agonist pancreatitis: 3 cases. JCEM Case Rep. 2025;3(7):luaf104. https:\/\/doi.org\/10.1210\/jcemcr\/luaf104.","journal-title":"JCEM Case Rep"},{"issue":"7","key":"3599_CR29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa167","volume":"105","author":"H Gnanapragasam","year":"2020","unstructured":"Gnanapragasam H, Mustafa N, Bierbrauer M, Andrea Providence T, Dandona P. Semaglutide in cystic fibrosis-related diabetes. J Clin Endocrinol Metab. 2020;105(7):dgaa167. https:\/\/doi.org\/10.1210\/clinem\/dgaa167.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3599_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.aed.2025.03.011","volume":"12","author":"R Auth","year":"2025","unstructured":"Auth R, Dougherty B, Putnam M, et al. Glucagon-like peptide 1 agonist use in an adult with cystic fibrosis-related diabetes and metabolic syndrome. AACE Endocrinol Diabetes. 2025;12(2):67\u201370. https:\/\/doi.org\/10.1016\/j.aed.2025.03.011.","journal-title":"AACE Endocrinol Diabetes"},{"key":"3599_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type\u00a02 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. https:\/\/doi.org\/10.1136\/bmj-2022-074068.","journal-title":"BMJ"},{"key":"3599_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3599_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613610","volume":"16","author":"X Xie","year":"2025","unstructured":"Xie X, Yang S, Deng S, Liu Y, Xu Z, He B. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type\u00a02 diabetes: a Bayesian network meta-analysis. Front Pharmacol. 2025;16:1613610. https:\/\/doi.org\/10.3389\/fphar.2025.1613610.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3599_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cgh.2012.11.006","volume":"11","author":"D Gelfond","year":"2013","unstructured":"Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol. 2013;11(4):333-e31. https:\/\/doi.org\/10.1016\/j.cgh.2012.11.006.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"3599_CR35","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.jcf.2017.07.004","volume":"16","author":"AJ Freeman","year":"2017","unstructured":"Freeman AJ, Ooi CY. Pancreatitis and pancreatic cystosis in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S79\u201386. https:\/\/doi.org\/10.1016\/j.jcf.2017.07.004.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"3599_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-021-00806-5","volume":"23","author":"JS Burton","year":"2021","unstructured":"Burton JS, Hachem C, Abraham JM. Luminal gastrointestinal manifestations of cystic fibrosis. Curr Gastroenterol Rep. 2021;23(3):4. https:\/\/doi.org\/10.1007\/s11894-021-00806-5.","journal-title":"Curr Gastroenterol Rep"},{"issue":"4","key":"3599_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jcf.2021.05.016","volume":"20","author":"S Henen","year":"2021","unstructured":"Henen S, Denton C, Teckman J, Borowitz D, Patel D. Review of gastrointestinal motility in cystic fibrosis. J Cyst Fibros. 2021;20(4):578\u201385. https:\/\/doi.org\/10.1016\/j.jcf.2021.05.016.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3599_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11894-023-00906-4","volume":"26","author":"D Patel","year":"2024","unstructured":"Patel D, Jose F, Baker J, Moshiree B. Neurogastroenterology and motility disorders of the gastrointestinal tract in cystic fibrosis. Curr Gastroenterol Rep. 2024;26(1):9\u201319. https:\/\/doi.org\/10.1007\/s11894-023-00906-4.","journal-title":"Curr Gastroenterol Rep"},{"issue":"7","key":"3599_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17476348.2023.2228194","volume":"17","author":"A Yule","year":"2023","unstructured":"Yule A, Sills D, Smith S, Spiller R, Smyth AR. Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis. Expert Rev Respir Med. 2023;17(7):547\u201361. https:\/\/doi.org\/10.1080\/17476348.2023.2228194.","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"3599_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","volume":"13","author":"CY Ooi","year":"2016","unstructured":"Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist\u2019s perspective. Nat Rev Gastroenterol Hepatol. 2016;13(3):175\u201385. https:\/\/doi.org\/10.1038\/nrgastro.2015.226.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3599_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcf.2023.01.010","volume":"22","author":"LR Caley","year":"2023","unstructured":"Caley LR, Zagoya C, Duckstein F, et al. Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis. J Cyst Fibros. 2023;22(2):275\u201381. https:\/\/doi.org\/10.1016\/j.jcf.2023.01.010.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3599_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","volume":"43","author":"M Wilschanski","year":"2024","unstructured":"Wilschanski M, Munck A, Carrion E, et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr. 2024;43(2):413\u201345. https:\/\/doi.org\/10.1016\/j.clnu.2023.12.017.","journal-title":"Clin Nutr"},{"issue":"8","key":"3599_CR43","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/oby.24336","volume":"33","author":"D Mozaffarian","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475\u2013503. https:\/\/doi.org\/10.1002\/oby.24336.","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"3599_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcf.2025.09.007","volume":"25","author":"R Kamoua","year":"2026","unstructured":"Kamoua R, Paradine K, McCoy L. Letter to the editor: semaglutide-associated recurrent distal intestinal obstruction in cystic fibrosis. J Cyst Fibros. 2026;25(1):179\u201380. https:\/\/doi.org\/10.1016\/j.jcf.2025.09.007.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"3599_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012798.pub3","volume":"12","author":"FJ Gilchrist","year":"2021","unstructured":"Gilchrist FJ, Green J, Carroll W. Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis. Cochrane Database Syst Rev. 2021;12(12):CD012798. https:\/\/doi.org\/10.1002\/14651858.CD012798.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3599_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae719","volume":"110","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1\u201315. https:\/\/doi.org\/10.1210\/clinem\/dgae719.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3599_CR47","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14740338.2023.2284992","volume":"23","author":"A Muhammed","year":"2024","unstructured":"Muhammed A, Thomas C, Kalaiselvan V, Undela K. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2024;23(6):731\u201342. https:\/\/doi.org\/10.1080\/14740338.2023.2284992.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"3599_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103116","volume":"18","author":"M Nassar","year":"2024","unstructured":"Nassar M, Nassar O, Abosheaishaa H, Misra A. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type\u00a02 diabetes or obesity with a history of acute pancreatitis: a propensity matched global federated TriNetX database-based retrospective cohort study. Diabetes Metab Syndr. 2024;18(9):103116. https:\/\/doi.org\/10.1016\/j.dsx.2024.103116.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"3599_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14309\/ajg.0000000000003525","volume":"121","author":"LM Nieto","year":"2026","unstructured":"Nieto LM, Martinez J, Narvaez SI, et al. Glucagon-like peptide-1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with type\u00a02 diabetes who develop acute pancreatitis: a multicenter analysis. Am J Gastroenterol. 2026;121(2):424\u201331. https:\/\/doi.org\/10.14309\/ajg.0000000000003525.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3599_CR50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","volume":"21","author":"MJ Gould","year":"2022","unstructured":"Gould MJ, Smith H, Rayment JH, Machida H, Gonska T, Galante GJ. CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis. J Cyst Fibros. 2022;21(4):600\u20132. https:\/\/doi.org\/10.1016\/j.jcf.2021.09.010.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"3599_CR51","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jcf.2023.02.013","volume":"22","author":"I Sadras","year":"2023","unstructured":"Sadras I, Cohen-Cymberknoh M, Kerem E, et al. Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators. J Cyst Fibros. 2023;22(4):777\u20139. https:\/\/doi.org\/10.1016\/j.jcf.2023.02.013.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3599_CR52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","volume":"134","author":"S Wharton","year":"2022","unstructured":"Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14\u20139. https:\/\/doi.org\/10.1080\/00325481.2021.2002616.","journal-title":"Postgrad Med"},{"issue":"1","key":"3599_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-002456","volume":"11","author":"M Almulhem","year":"2024","unstructured":"Almulhem M, Ward C, Haq I, Gray RD, Brodlie M. Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review. BMJ Open Respir Res. 2024;11(1):e002456. https:\/\/doi.org\/10.1136\/bmjresp-2024-002456.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"3599_CR54","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jcf.2022.12.013","volume":"22","author":"K Dong","year":"2023","unstructured":"Dong K, Huh SM, Lam GY, et al. Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis. J Cyst Fibros. 2023;22(2):306\u201312. https:\/\/doi.org\/10.1016\/j.jcf.2022.12.013.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3599_CR55","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jcf.2023.10.004","volume":"23","author":"LS Gold","year":"2024","unstructured":"Gold LS, Hansen RN, Heltshe SL, et al. Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location. J Cyst Fibros. 2024;23(2):278\u201381. https:\/\/doi.org\/10.1016\/j.jcf.2023.10.004.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"3599_CR56","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jcf.2023.06.011","volume":"22","author":"L Merjaneh","year":"2023","unstructured":"Merjaneh L, Sidhaye AR, Vu PT, et al. Role of hyperglycemia in cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2023;22(5):868\u201374. https:\/\/doi.org\/10.1016\/j.jcf.2023.06.011.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"3599_CR57","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.ajkd.2022.10.012","volume":"81","author":"KE Watson","year":"2023","unstructured":"Watson KE, Dhaliwal K, Robertshaw S, et al. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. Am J Kidney Dis. 2023;81(5):564\u201374. https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.012.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3599_CR58","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa2407379","volume":"392","author":"CK Fox","year":"2025","unstructured":"Fox CK, Barrientos-P\u00e9rez M, Bomberg EM, et al. liraglutide for children 6 to <12\u00a0years of age with obesity - a randomized trial. N Engl J Med. 2025;392(6):555\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2407379.","journal-title":"N Engl J Med"},{"issue":"22","key":"3599_CR59","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1916038.","journal-title":"N Engl J Med"},{"key":"3599_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2025.3243","author":"P Kotecha","year":"2025","unstructured":"Kotecha P, Huang W, Yeh YY, et al. Efficacy and safety of GLP-1 RAs in children and adolescents with obesity or type\u00a02 diabetes: a systematic review and meta-analysis. JAMA Pediatr. 2025. https:\/\/doi.org\/10.1001\/jamapediatrics.2025.3243.","journal-title":"JAMA Pediatr"},{"issue":"11","key":"3599_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013755.pub2","volume":"11","author":"A Toner","year":"2021","unstructured":"Toner A, McCloy A, Dyce P, Nazareth D, Frost F. Continuous glucose monitoring systems for monitoring cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2021;11(11):CD013755. https:\/\/doi.org\/10.1002\/14651858.CD013755.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"3599_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100307","volume":"30","author":"H Crow","year":"2022","unstructured":"Crow H, Bengtson C, Shi X, Graves L 3rd, Anabtawi A. CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy. J Clin Transl Endocrinol. 2022;30:100307. https:\/\/doi.org\/10.1016\/j.jcte.2022.100307.","journal-title":"J Clin Transl Endocrinol"},{"issue":"19","key":"3599_CR63","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1908639.","journal-title":"N Engl J Med"},{"issue":"2","key":"3599_CR64","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, et al. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):265\u201371. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.012.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3599_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","volume":"24","author":"GA Ratti","year":"2025","unstructured":"Ratti GA, Smith H, Mirfakhraee S, et al. Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor. J Cyst Fibros. 2025;24(1):47\u201352. https:\/\/doi.org\/10.1016\/j.jcf.2024.09.022.","journal-title":"J Cyst Fibros"},{"issue":"19","key":"3599_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/nu16193293","volume":"16","author":"F Hevilla","year":"2024","unstructured":"Hevilla F, Porras N, Gir\u00f3n MV, et al. Impact of elexacaftor-tezacaftor-ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study. Nutrients. 2024;16(19):3293. https:\/\/doi.org\/10.3390\/nu16193293.","journal-title":"Nutrients"},{"key":"3599_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1477674","volume":"11","author":"A Merino S\u00e1nchez-Ca\u00f1ete","year":"2024","unstructured":"Merino S\u00e1nchez-Ca\u00f1ete A, L\u00f3pez C\u00e1rdenes CM, Vicente Santamar\u00eda S, et al. Increased fat mass and obesity risk after elexacaftor-tezacaftor-ivacaftor therapy in young adults with cystic fibrosis. Front Nutr. 2024;11:1477674. https:\/\/doi.org\/10.3389\/fnut.2024.1477674.","journal-title":"Front Nutr"},{"issue":"3","key":"3599_CR68","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41574-025-01196-8","volume":"22","author":"A Moheet","year":"2026","unstructured":"Moheet A, Scully KJ, Harindhanavudhi T, et al. The endocrine complications of cystic fibrosis. Nat Rev Endocrinol. 2026;22(3):177\u201391. https:\/\/doi.org\/10.1038\/s41574-025-01196-8.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"3599_CR69","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2337\/dc23-1287","volume":"47","author":"B Zhang","year":"2024","unstructured":"Zhang B, Cheng Z, Chen J, et al. Efficacy and safety of mazdutide in Chinese patients with type\u00a02 diabetes: a randomized, double-blind, placebo-controlled phase\u00a02 trial. Diabetes Care. 2024;47(1):160\u20138. https:\/\/doi.org\/10.2337\/dc23-1287.","journal-title":"Diabetes Care"},{"issue":"3","key":"3599_CR70","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","volume":"67","author":"M Bl\u00fcher","year":"2024","unstructured":"Bl\u00fcher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type\u00a02 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470\u201382. https:\/\/doi.org\/10.1007\/s00125-023-06053-9.","journal-title":"Diabetologia"},{"issue":"10401","key":"3599_CR71","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type\u00a02 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase\u00a02 trial conducted in the USA. Lancet. 2023;402(10401):529\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X.","journal-title":"Lancet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03599-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:21:25Z","timestamp":1782206485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03599-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03599-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Theodoros Panou has nothing to disclose. Evanthia Gouverihas attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly, Boehringer Ingelheim, Menarini, Petsiavas and KRKA Hellas; received speaker honoraria by AstraZeneca, Boehringer Ingelheim, Sanofi, Menarini. Djordje S. Popovic declares associations with: Abbott (speaker honoraria), ADOC Pharma (sponsored conferences) Alkaloid (speaker honoraria), Amicus (speaker honoraria, sponsored conferences), AstraZeneca (speaker honoraria), Boehringer Ingelheim (speaker honoraria), Berlin-Chemie (speaker honoraria), Eli Lilly (advisory board member, speaker honoraria, sponsored conferences), Galenika (speaker honoraria), Krka (speaker honoraria), Merck (speaker honoraria, sponsored conferences), Novo Nordisk (advisory board member, speaker honoraria, sponsored conferences, participation in sponsored studies), PharmaSwiss (speaker honoraria), Sanofi-Aventis (speaker honoraria, sponsored conferences, participation in sponsored studies), Servier (speaker honoraria), Viatris (speaker honoraria), and W\u00f6rwag Pharma (speaker honoraria, sponsored conferences). Nikolaos Papanas has been an advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Roche, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, ELPEN, Galenica, KRKA, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda, Viatris and Vianex; and attended conferences sponsored by TrigoCare International, Bayer, Eli Lilly, Galenica, Novo Nordisk, Pfizer, Viatris and Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}